Sanofi SA (EPA:SAN) received a €95.00 ($105.56) price target from Deutsche Bank AG in a research note issued on Thursday. The brokerage presently has a a “buy” rating on the stock.

A number of other research firms also recently commented on SAN. Jefferies Group set a €74.00 ($82.22) price objective on Sanofi SA and gave the stock a “neutral” rating in a report on Thursday. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Sanofi SA in a research report on Tuesday, October 4th. BNP Paribas set a €78.00 ($86.67) price target on shares of Sanofi SA and gave the stock a “neutral” rating in a research report on Wednesday, September 14th. Berenberg Bank set a €93.00 ($103.33) price target on shares of Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, September 8th. Finally, Kepler Capital Markets set a €89.00 ($98.89) price target on shares of Sanofi SA and gave the stock a “buy” rating in a research report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of €86.18 ($95.75).

Analyst Recommendations for Sanofi SA (EPA:SAN)

Sanofi SA (EPA:SAN) traded down 1.12% during mid-day trading on Thursday, hitting €67.71. The stock had a trading volume of 1,768,014 shares. The stock has a market cap of €87.14 billion and a P/E ratio of 21.05. The company has a 50 day moving average price of €25.98 and a 200 day moving average price of €25.76. Sanofi SA has a one year low of €22.81 and a one year high of €68.17.

Sanofi SA Company Profile

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.